| NCT ID | NCT06747806 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Chicago |
| Condition | Cardiovascular Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2023-12-18 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2023-12-18 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Treatment strategies for cardiac surgery patients have been evolving significantly for the last decade. While clinical outcomes have been improving, there are still significant areas unexplored in these patients. Cardiac surgery, or cardiovascular surgery, is surgery on the heart or great vessels performed by cardiac surgeons. It is often used to treat complications of ischemic heart disease (for example, with coronary artery bypass grafting); to correct congenital heart disease; or to treat valvular heart disease from various causes, including endocarditis, rheumatic heart disease, and atherosclerosis. Biobanking is a fundamental process required in the better understanding of human diseases together with their underlying mechanisms. Biobanking refers to the process by which samples of bodily fluid or tissue are collected for research use to improve the understanding of health and disease. For this study, the investigator's objective is to acquire elucidation in disease etiology, translation, and advancing public health by evaluating blood and tissue results of those with cardiac disease undergoing cardiac surgery.
Eligibility Criteria
Inclusion Criteria: * All patients who undergo cardiac surgery at Advocate Children's Hospital (ACH)\& University of Chicago Medical Center (UCMC) by the ACH \& UC Cardiothoracic Surgery Research team who are pediatric neonates and up. * Patients will only be English speaking. Exclusion Criteria: * Vulnerable Subjects/Subject Capacity to provide consent
Contact & Investigator
Valluvan Jeevanandam, MD
PRINCIPAL INVESTIGATOR
University of Chicago
Frequently Asked Questions
Who can join the NCT06747806 clinical trial?
This trial is open to participants of all sexes, studying Cardiovascular Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06747806 currently recruiting?
Yes, NCT06747806 is actively recruiting participants. Contact the research team at jeevan@bsd.uchicago.edu for enrollment information.
Where is the NCT06747806 trial being conducted?
This trial is being conducted at Hyde Park, United States.
Who is sponsoring the NCT06747806 clinical trial?
NCT06747806 is sponsored by University of Chicago. The principal investigator is Valluvan Jeevanandam, MD at University of Chicago. The trial plans to enroll 500 participants.